Q BioMed (QBIO) 10-Q 15 Oct 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Aug. 31, 2021	Oct. 13, 2021
Document and Entity Information
Document Type	10-Q
Document Period End Date	Aug. 31, 2021
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-55535
Entity Registrant Name	Q BIOMED INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	30-0967746
Entity Current Reporting Status	Yes
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--11-30
Entity Address, Address Line One	366 Madison Avenue, 3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	588-0022
Document Quarterly Report	true
Entity Central Index Key	0001596062
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Trading Symbol	QBIO
Title of 12(b) Security	None
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,598,588

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Aug. 31, 2021	Nov. 30, 2020
Current assets:
Cash	$ 151,214	$ 177,145
Accounts receivable	38,875
Prepaid expenses and other current assets	48,967	46,339
Total current assets	239,056	223,484
Intangible assets, net	362,500	400,000
Total Assets	601,556	623,484
Current liabilities:
Accounts payable	1,374,199	721,744
Accrued expenses	909,606	837,660
Accrued expenses - related party	101,500	4,000
Accrued interest payable	22,438	43,376
Convertible notes payable, net	1,190,292	92,185
Total current liabilities	3,598,035	1,698,965
Long-term liabilities:
Total Liabilities	3,598,035	1,698,965
Commitments and Contingencies (Note 6)
Stockholders' Deficit:
Preferred stock
Common stock, $0.001 par value; 250,000,000 shares authorized; 27,974,345 and 23,816,489 shares issued and outstanding as of August 31, 2021 and November 30, 2020, respectively	27,974	23,816
Additional paid-in capital	52,955,192	47,656,423
Accumulated deficit	(62,056,744)	(55,886,068)
Total Stockholders' Deficit	(2,996,479)	(1,075,481)
Total Liabilities and Stockholders' Deficit	601,556	623,484
Convertible Series A Preferred Stock
Stockholders' Deficit:
Preferred stock	2,161,587	2,161,980
Convertible Series B Preferred Stock
Stockholders' Deficit:
Preferred stock	$ 3,915,512	$ 4,968,368

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2021	Nov. 30, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	27,974,345	23,816,489
Common stock, shares outstanding	27,974,345	23,816,489
Convertible Series A Preferred Stock
Preferred stock, shares authorized	500,000	500,000
Preferred stock, issued	227,998	227,998
Preferred stock, outstanding	227,998	227,998
Convertible Series B Preferred Stock
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	400,000	503,134
Preferred stock, outstanding	400,000	503,134

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Condensed Consolidated Statements of Operations
Net Sales	$ 45,675	$ 15,000	$ 90,675	$ 30,000
Cost of sales	73,770	158,516	160,763	193,211
Gross loss	(28,095)	(143,516)	(70,088)	(163,211)
Operating expenses:
General and administrative expenses	1,371,676	1,491,613	5,028,668	8,659,819
Research and development expenses	202,168	613,707	667,538	896,908
Total operating expenses	1,573,844	2,105,320	5,696,206	9,556,727
Loss from operations	(1,601,939)	(2,248,836)	(5,766,294)	(9,719,938)
Other (income) expenses:
Interest expense	99,418	9,025	234,752	291,626
Change in fair value of embedded derivatives	101,247	0	128,720	19,163
Loss on debt extinguishment	(15,212)	0	40,910	31,399
Total other expenses	185,453	9,025	404,382	342,188
Net loss	(1,787,392)	(2,257,861)	(6,170,676)	(10,062,126)
Accumulated dividend on convertible preferred stock	(125,485)	(146,227)	(375,517)	(230,699)
Deemed dividend on convertible preferred stock due to beneficial conversion feature	0	0	0	(482,945)
Net loss attributable to common stockholders	$ (1,912,877)	$ (2,404,088)	$ (6,546,193)	$ (10,775,770)
Net loss per share - basic	$ (0.07)	$ (0.11)	$ (0.25)	$ (0.50)
Net loss per share - diluted	$ (0.07)	$ (0.11)	$ (0.25)	$ (0.50)
Weighted average shares outstanding, basic	27,660,616	22,433,141	26,207,685	21,731,159
Weighted average shares outstanding, diluted	27,660,616	22,433,141	26,207,685	21,731,159

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Preferred stockSeries A convertible preferred stock	Preferred stockSeries B convertible preferred stock	Common StockSeries B convertible preferred stock	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Beginning balance, Shares at Nov. 30, 2019			19,709,068
Beginning balance, Amount at Nov. 30, 2019				$ 19,709	$ 37,328,827	$ (42,393,877)	$ (5,045,341)
Issuance of Series A and Series B preferred stock for cash, Amount	$ 975,000	$ 2,975,000					3,950,000
Number of shares issued for cash	100,000	300,000
Issuance of Series A and Series B preferred stock to convert notes payable, Amount	$ 1,279,980	$ 2,031,340					3,311,320
Issuance of Series A and Series B preferred stock to convert notes payable, Shares	127,998	203,134
Offering cost related issuance of Series A and Series B preferred stock	$ (138,600)	$ (138,600)			277,200
Cashless warrants exercise, Amount				21	(21)
Cashless warrants exercise, Shares			20,860
Beneficial conversion feature of Series A convertible preferred stock	(252,786)				252,786
Beneficial conversion feature related to convertible notes							0
Beneficial conversion feature of Series B convertible preferred stock		(230,159)			230,159
Deemed dividends related to immediate accretion of beneficial conversion feature of convertible preferred stock	252,786				(252,786)
Deemed dividends related to immediate accretion of beneficial conversion feature of Series B convertible preferred stock		230,159			(230,159)
Accrued dividend on preferred stock	$ 73,466	$ 157,233			(230,699)
Share based compensation for services, Amount				233	4,982,213		4,982,446
Share based compensation for services, Shares			233,106
Share based compensation related to warrants modification, Amount					255,008		255,008
Value of shares issued for conversion				$ 2,811	2,732,489		2,735,300
Issuance of common stock to convert notes payable (in shares)			2,811,198
Net loss						(10,062,126)	(10,062,126)
Ending balance, Shares at Aug. 31, 2020	227,998	503,134	22,774,232	22,774,232
Ending balance, Amount at Aug. 31, 2020	$ 2,189,846	$ 5,024,973		$ 22,774	45,345,017	(52,456,003)	126,607
Beginning balance, Shares at May. 31, 2020	227,998	503,134		22,650,685
Beginning balance, Amount at May. 31, 2020	$ 2,144,246	$ 4,924,346		$ 22,650	45,219,938	(50,198,142)	2,113,038
Accrued dividend on preferred stock	$ 45,600	$ 100,627			(146,227)
Share based compensation for services, Amount				$ 124	271,306		271,430
Share based compensation for services, Shares				123,547
Net loss						(2,257,861)	(2,257,861)
Ending balance, Shares at Aug. 31, 2020	227,998	503,134	22,774,232	22,774,232
Ending balance, Amount at Aug. 31, 2020	$ 2,189,846	$ 5,024,973		$ 22,774	45,345,017	(52,456,003)	126,607
Beginning balance, Shares at Nov. 30, 2020	227,998	503,134		23,816,489
Beginning balance, Amount at Nov. 30, 2020	$ 2,161,980	$ 4,968,368		$ 23,816	47,656,423	(55,886,068)	(1,075,481)
Issuance of common stock and warrants for cash				$ 1,213	908,787		910,000
Issuance of common stock and warrants for cash (in shares)				1,213,333
Issuance of common stock for cash				$ 100	99,900		100,000
Issuance of warrants in conjuction with convertible note					252,683		252,683
Issuance of common stock for cash (in shares)				100,000
Beneficial conversion feature related to convertible notes					290,967		290,967
Issuance common stock for dividend payment on preferred stock	(136,799)	(260,627)		$ 386	397,040
Issuance common stock for dividend payment on preferred stock				385,846
Share based compensation for services, Amount				$ 710	2,243,646		2,244,356
Share based compensation for services, Shares				709,436
Value of shares issued for conversion				$ 469	416,378		416,847
Issuance of common stock to convert notes payable (in shares)				469,152
Issuance of common stock to convert Series B preferred stock		$ (1,031,340)		$ 1,245	1,030,095
Issuance of common stock to convert Series B preferred stock (in shares)		(103,134)		1,245,089
Issuance cost related to issuance of convertible notes				$ 35	34,790		34,825
Issuance cost related to issuance of convertible notes (in shares)				35,000
Accumulated dividend on convertible preferred stock	$ 136,406	$ 239,111			(375,517)
Net loss						(6,170,676)	(6,170,676)
Ending balance, Shares at Aug. 31, 2021	227,998	400,000		27,974,345
Ending balance, Amount at Aug. 31, 2021	$ 2,161,587	$ 3,915,512		$ 27,974	52,955,192	(62,056,744)	(2,996,479)
Beginning balance, Shares at May. 31, 2021	227,998	400,000		27,456,512
Beginning balance, Amount at May. 31, 2021	$ 2,161,702	$ 3,915,512		$ 27,456	51,972,556	(60,269,352)	(2,192,126)
Issuance of common stock and warrants for cash	(45,600)	(80,000)		$ 131	125,469
Issuance of common stock and warrants for cash (in shares)				130,833
Issuance of warrants in conjuction with convertible note					252,683		252,683
Beneficial conversion feature related to convertible notes					225,750		225,750
Share based compensation for services, Amount				$ 86	290,687		290,773
Share based compensation for services, Shares				85,628
Value of shares issued for conversion				$ 301	213,532		213,833
Issuance of common stock to convert notes payable (in shares)				301,372
Accumulated dividend on convertible preferred stock	$ 45,485	$ 80,000			(125,485)
Net loss						(1,787,392)	(1,787,392)
Ending balance, Shares at Aug. 31, 2021	227,998	400,000		27,974,345
Ending balance, Amount at Aug. 31, 2021	$ 2,161,587	$ 3,915,512		$ 27,974	$ 52,955,192	$ (62,056,744)	$ (2,996,479)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Cash flows from operating activities:
Net loss	$ (6,170,676)	$ (10,062,126)
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services	2,244,356	4,982,446
Share based compensation related to warrants modification	0	255,008
Change in fair value of embedded conversion option	128,720	19,163
Accretion of debt discount	188,118	136,705
Amortization expense	37,500	37,500
Loss on debt extinguishment	40,910	31,399
Changes in operating assets and liabilities:
Accounts receivable	(38,875)	(12,300)
Prepaid expenses and other current assets	(2,628)	(116,302)
Accounts payable and accrued expenses	851,332	(187,667)
Accrued interest payable	(20,938)	154,897
Net cash used in operating activities	(2,742,181)	(4,761,277)
Cash flows from financing activities:
Proceeds from issuance of Series A and Series B convertible preferred stock, net of issuance costs	0	3,950,000
Proceeds received from issuance of convertible notes, net	1,706,250	1,965,000
Proceeds received from issuance of notes to related parties	30,000	0
Proceeds received for issuance of common stock and warrants	1,010,000	0
Repayment of notes to related parties	(30,000)	0
Net cash provided by financing activities	2,716,250	5,915,000
Net (decrease) increase in cash	(25,931)	1,153,723
Cash at beginning of period	177,145	172,636
Cash at end of the period	151,214	1,326,359
Supplemental disclosures:
Cash paid for interest to related parties	(441)	0
Cash paid for income taxes	0	0
Supplemental disclosures for noncash investing and financing activities:
Issuance of common stock to convert notes payable and accrued interest	416,847	2,735,300
Issuance of Series A and Series B preferred stock in exchange for outstanding convertible notes payable and accrued interest	0	3,311,320
Issuance of common stock to convert Series B preferred stock	1,031,340	0
Accumulated dividend on convertible preferred stock	375,517	230,699
Shares payable related to debt modification	0	10,000
Issuance of common stock for dividend payment on preferred stock	397,426	0
Beneficial conversion feature related to convertible notes	290,967	0
Offering cost	$ 69,825	$ 0

Organization of the Company and

Organization of the Company and Description of the Business	9 Months Ended
	Aug. 31, 2021
Organization of the Company and Description of the Business
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed”), and its wholly owned subsidiaries Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG (collectively, “the Company”), is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or the spinoff of new public companies. The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation and Going

Basis of Presentation and Going Concern	9 Months Ended
	Aug. 31, 2021
Basis of Presentation and Going Concern
Basis of Presentation and Going Concern	Note 2 - Basis of Presentation and Going Concern Basis of Presentation The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended November 30, 2020. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year. Going Concern The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management will be forced to scale back the Company’s operations or cease its operations. Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. COVID 19 The impact of the worldwide spread of a novel strain of coronavirus (“COVID-19”) has been unprecedented and unpredictable, but based on the Company’s current assessment, the Company does not expect any material impact on its long-term strategic plans, operations and its liquidity due to the worldwide spread of COVID-19. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world and its assessment of the impact of COVID-19 may change.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Aug. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2020 included in the Company’s Form 10-K. Common Stock Warrants The Company classifies as equity any warrants that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any warrants that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope exception. The Company assesses classification of its common stock warrants at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the criteria for equity or liability classification in the balance sheet. The warrants classified as liability are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the consolidated statements of operations at each period end while such instruments remain outstanding.

Loss per share

Loss per share	9 Months Ended
	Aug. 31, 2021
Loss per share
Loss per share	Note 4 - Loss per share Basic net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ ​ Potentially dilutive securities August 31, 2021 November 30, 2020 Series A convertible preferred stock ​ 2,280,000 ​ 2,280,000 Series B convertible preferred stock ​ 4,000,000 ​ 5,031,000 Common stock purchase warrants ​ 11,752,000 ​ 10,023,000 Stock Options ​ 3,850,000 ​ 3,850,000 Convertible Notes 2,272,000 56,000 Potentially dilutive securities 24,154,000 21,240,000 ​

Outstanding Debt

Outstanding Debt	9 Months Ended
	Aug. 31, 2021
Outstanding Debt
Outstanding Debt	Note 5 - Outstanding Debt ​ Convertible Notes ​ The table below summarizes outstanding convertible notes as of August 31, 2021 and November 30, 2020 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ August 31, 2021 November 30, 2020 Convertible Notes Payable: ​ ​ ​ ​ ​ ​ Principal value of 2020 Debenture ​ $ 300,000 ​ $ — Fair value of bifurcated contingent put option ​ 39,000 ​ — Debt discount ​ (35,000) ​ — Carrying value of 2020 Debenture ​ ​ 304,000 ​ ​ — Principal value of 2021 Debenture ​ 1,306,000 ​ — Fair value of bifurcated contingent put option ​ ​ 391,000 ​ ​ — Debt discount ​ ​ (811,000) ​ ​ — Carrying value of 2021 Debenture ​ ​ 886,000 ​ ​ — Principal value of 2019 August Debenture ​ ​ — ​ ​ 100,000 Debt discount ​ ​ — ​ ​ (8,000) Carrying value of 2019 August Debenture ​ ​ — ​ ​ 92,000 Total carrying value of convertible notes payable ​ $ 1,190,000 ​ $ 92,000 ​ 2020 Debenture On December 23, 2020, the Company issued a debenture for $0.5 million (the “2020 Debenture”) pursuant to a securities purchase agreement with an accredited investor (the “Holder”). The debenture has a maturity date of the earlier of (a) June 23, 2021, or (b) the closing of the next financing transaction, or series or transactions, pursuant to which the Company raises net proceeds of at least $1.0 million, or as may be extended at the option of the Holder. The 2020 Debenture may be converted at any time on or prior to maturity at the lower of $2.70 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2020 Debenture, the conversion price may never be less than $1.00. The debenture bears interest at the rate of 5.5% per annum, and on issuance, the Company paid to the holder a commitment fee equal to 2% of the amount of the debenture. On July 22, 2021, the Company entered into an amendment agreement to the securities purchase agreement with the Holder, pursuant to which, the floor price of the 2020 Debenture was reduced to $0.50 per share. Additionally, the maturity date of the 2020 Debenture was extended to December 31, 2021. The amendment was recognized as a debt extinguishment, resulting in a gain on debt extinguishment of approximately $15,000. 2021 Debentures February Debenture On February 12, 2021, the Company issued a debenture for $0.5 million (the “February Debenture”) pursuant to a securities purchase agreement with an accredited investor dated February 12, 2021. The February Debenture may be converted at any time on or prior to maturity at the lower of $1.15 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2020 Debenture, the conversion price may never be less than $1.00. The debenture has a maturity date of February 12, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The debenture bears interest at the rate of 5.5% per annum, and on issuance, the Company paid to the holder a commitment fee equal to 2% of the amount of the debenture. July Debenture On July 26, 2021, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “July Debenture”) in the principal amount of $806,250 and a warrant to purchase up to 645,000 shares of common stock (the “Warrant”) for a total purchase price of $750,000. The July Debenture has a maturity date of April 26, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The July Debenture carries an interest rate of 10% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 15% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance. The holder may convert the July Debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 85% of the average of the four (4) lowest VWAPs during the 20 Trading Days prior to the date of such calculation. The Warrant has an exercise price of $1.25 and may be exercised in cash or via cashless exercise, exercisable for five (5) years from issuance. The grant date relative fair value of the Warrant was estimated to be $253,000 as determined based on the relative fair value allocation of the proceeds received. The Warrant were valued using the Black-Scholes option pricing model using the following inputs: ​ ​ ​ ​ ​ ​ Strike price $ 1.25 ​ Terms (years) ​ 5.0 ​ Volatility ​ 112 % Risk-free rate ​ 0.7 % Dividend yield ​ 0 % ​ Upon issuance of the 2020 Debenture and 2021 Debentures, the Company recognized a debt discount of approximately $978,000, resulting from the recognition of issuance costs of $170,000, beneficial conversion feature of $291,000, relative fair value of the Warrant of $253,000, and bifurcated embedded derivatives of $264,000. The contingent share-settled redemption feature and contingent prepayment provision within the 2020 Debenture and the 2021 Debenture are both contingent put options that are required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of the prepayment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ July 26, 2021 February 12, 2021 December 23, 2020 ​ Strike price ​ $ 1.00 ​ $ 1.15 ​ $ 2.70 ​ Terms (years) ​ ​ 0.8 ​ ​ 1.0 ​ ​ 0.5 ​ Volatility ​ ​ 62 % ​ 92 % ​ 92 % Risk-free rate ​ ​ 0.1 % ​ 0.1 % ​ 0.1 % Dividend yield ​ ​ 0 % ​ 0 % ​ 0 % ​ The fair value of the contingent put option in all outstanding debentures with the feature are revalued as of August 31, 2021 based on the following weighted average key inputs: ​ ​ ​ ​ ​ ​ ​ ​ August 31, 2021 ​ ​ Strike price ​ $ 1.36 ​ ​ Terms (years) ​ ​ 0.5 ​ ​ Volatility ​ $ 0.66 ​ ​ Risk-free rate ​ ​ 0.1 % ​ Dividend yield ​ ​ 0 % ​ ​ The following table presents changes in Level 3 liabilities measured at fair value for nine months ended August 31, 2021. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ Balance – December 1, 2020 $ — Additional derivative liability ​ 326,000 Debt extinguishment ​ (25,000) Change in fair value ​ 129,000 Balance – August 31, 2021 ​ $ 430,000 ​ Notes Payable – Related Parties ​ On April 16, 2021, the Company entered into two unsecured promissory notes agreement (the “Notes”) with certain management personnel for an aggregate principal amount of $30,000. The Notes bear interest at 5% per annum and are payable by August 31, 2021. ​ During the quarter ended August 31, 2021, the Company made full repayment of $30,000 to the management personnel, including all outstanding interest. ​ Interest expense ​ Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the nine months ended ​ August 31, 2021 August 31, 2020 August 31, 2021 August 31, 2020 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 21,000 ​ $ 6,000 ​ $ 46,000 ​ $ 156,000 Accretion of debt discount ​ ​ 78,000 ​ ​ 3,000 ​ ​ 188,000 ​ ​ 136,000 Total interest expense ​ $ 99,000 ​ $ 9,000 ​ $ 234,000 ​ $ 292,000 ​

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Aug. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	Note 6 - Commitments and Contingencies Equity Financing ​ On May 5, 2021, the Company entered into an agreement with Aedesius Holdings Ltd. (“Aedesius”) pursuant to which the Company has agreed with Aedesius that the Company would sell it up to 16,000,000 units (the “Units”) for a total aggregate of up to $20,000,000. ​ Aedesius failed to perform on its obligation and to date has not invested any monies in the Company. As a result, the Company has terminated any and all rights with respect to future fundings and will pursue whatever rights and remedies the Company has at its disposal for breach of contract. The Company is now focused on its uplisting and the related funding previously registered on Form S-1 with SEC. Legal Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Advisory Agreements The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received. Lease Agreement In December 2016, one of our subsidiaries entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ended in December 2019, and the Company has renewed its office lease agreement for another three years with the same terms. This agreement does not identify a specific asset and does not convey the use of substantially all of the shared office capacity. As such, this agreement does not contain a lease under ASC 842. The Company recognizes monthly license payments as incurred over the term of the arrangement. Rent expense is classified within general and administrative expenses on a straight-line basis.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Aug. 31, 2021
Related Party Transactions
Related Party Transactions	Note 7 - Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the nine months ended ​ August 31, 2021 August 31, 2020 August 31, 2021 August 31, 2020 Consulting and legal expenses ​ $ 105,000 ​ $ 105,000 ​ $ 315,000 ​ $ 210,000 ​ On February 1, 2021, the Company issued 35,000 shares to Mr. Rosenstadt, the Company’s Chief Legal Officer and director, for his services performed in connection with December 2020 financing. The fair value was approximate $35,000, which was recorded as part of debt issuance cost to the 2020 Debenture (see note 5). ​ On April 16, 2021, the Company entered into two unsecured promissory note agreements (the “Notes”) with certain management personnel for an aggregate principal amount of $30,000. The Notes bear interest at 5% per annum and are payable by August 31, 2021. During the quarter ended August 31, 2021, the Company made full repayment of $30,000 to the management personnel, including all outstanding interest.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Aug. 31, 2021
Stockholders' Deficit
Stockholders' Deficit	Note 8 - Stockholders’ Deficit Preferred Shares The original issue price and the liquidation value per share, as of August 31, 2021, of each class of preferred stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price Liquidation Value ​ ​ Per Share ​ Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.20 ​ During the nine months ended August 31, 2021, the Company issued total 385,846 shares of common stock as dividend payment on Series A and Series B preferred stock. The Company had accumulated dividends payable on the Preferred Shares of approximately $0.1 million as of August 31, 2021. Common Shares Between January and February 2021, the Company issued 1,245,089 shares of common stock to convert approximately 103,000 shares of Series B preferred stock. On February 26, 2021, the Company issued 100,000 shares of common stock for cash proceeds of $0.1 million. On May 20, 2021, the Company entered into a series of securities purchase agreements for the sale of 1,213,333 units at a $0.75 per unit sales price. The Company raised approximately $0.9 million in cash. Each unit consisted of one common share and one warrant to purchase one share of common stock at an exercise price of $1.25. The common warrants issued on May 20, 2021 have a fair value of $0.80 per share, see Note 9. On June 3, 2021, the Company issued 130,833 shares of common stock as dividend payment on Series A and Series B preferred stock. During the nine months ended August 31, 2021, the Company issued 469,152 shares of common stock to convert $0.4 million of outstanding debt and interest. During the nine months ended August 31, 2021, the Company issued an aggregate of 709,436 shares of the Company’s common stock to various vendors for advisory services, valued at approximately $0.7 million based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

Warrants and Options

Warrants and Options	9 Months Ended
	Aug. 31, 2021
Warrants and Options
Warrants and Options	Note 9 - Warrants and Options Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services, warrants issued as part of the units sold in the private placements and warrants issued in conjunction with convertible debenture, at August 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Contractual ​ ​ ​ ​ ​ Warrants ​ Exercise Price ​ Life (years) ​ Intrinsic Value Outstanding at December 1, 2020 10,023,000 ​ $ 2.09 3.2 ​ $ 870,000 Issued 1,879,000 ​ ​ 1.25 4.8 ​ ​ — Forfeited/expired (150,000) ​ ​ — — ​ ​ — Outstanding at August 31, 2021 11,752,000 ​ $ 1.97 2.8 ​ $ 415,000 Exercisable at August 31, 2021 11,752,000 ​ $ 1.97 2.8 ​ $ 415,000 ​ Warrants issued during the nine months ended August 31, 2021 were all equity classified. The fair value of the warrants was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ For the nine months ​ ​ ​ ended ​ ​ August 31, 2021 Strike price ​ $ 1.25 ​ Terms (years) ​ 5.0 ​ Volatility ​ 114 % Risk-free rate ​ 0.8 % Dividend yield ​ 0 % ​ Options Issued for Services The following represents a summary of all outstanding options to purchase the Company’s common stock at August 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at December 1, 2020 3,850,000 ​ $ 1.23 4.0 ​ $ 119,000 Issued — ​ ​ — — ​ ​ — Outstanding at August 31, 2021 3,850,000 ​ $ 1.23 4.0 ​ $ — Exercisable at August 31, 2021 3,425,000 ​ $ 1.26 2.8 ​ $ — ​ Stock-based Compensation The Company recognized general and administrative expenses of approximately $2.2 million and $5.0 million as a result of the shares, outstanding warrants and options issued to consultants and employees during the nine months ended August 31, 2021 and 2020, respectively. As of August 31, 2021, the estimated unrecognized stock-based compensation associate with these agreements is approximately $56,000 and will be fully recognized by November 30, 2021.

Subsequent Events

Subsequent Events	9 Months Ended
	Aug. 31, 2021
Subsequent Events
Subsequent Events	Note 10 - Subsequent Events On September 29, 2021, the Company entered into a securities purchase agreement with an accredited investor (“Lender”), pursuant to which it sold a convertible debenture (the “Debenture”) with a maturity date of 12 months after the issuance thereof for $2,000,000. The closing date of the sale was on October 5, 2021. The Debenture in the aggregate principal amount of $2,200,000 (the “Transaction”) which includes an original issue discount of $185,000 and $15,000 for the payment of the Lender’s legal fees and carries an interest rate of 6% per annum. The Company may prepay the Debenture at 105% of the outstanding aggregate principal amount plus accrued interest within the first 60 days of issuance, at 112% of the outstanding aggregate principal amount plus accrued interest from 61-120 days after issuance and at 124% of the outstanding aggregate principal amount plus accrued interest from 121-180 days after issuance. The Debenture may not be prepaid after 180 days. The Lender has the right to convert all or any amount of the outstanding aggregate principal amount at any time at a fixed conversion price of $1.00 per share. The conversion price after six months shall be fixed to $0.50 per share. However, in the event the Company’s Common Stock trades below $0.50 per share for more than ten (10) consecutive trading days, the Lender is entitled to convert all or any amount of the outstanding aggregate principal amount into shares of the Company’s Common Stock at a Conversion Price for each share of Common Stock equal to 85% of the average of the 4 lowest VWAP’s in the prior 20 trading days. On September 2, 2021, the Company issued 147,764 shares of common stock as dividend payment on Series A and Series B During September 2021, the Company issued 476,479 shares of common stock to convert $0.3 million of outstanding debt and interest.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Aug. 31, 2021
Summary of Significant Accounting Policies
Recent accounting standards	Common Stock Warrants The Company classifies as equity any warrants that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any warrants that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope exception. The Company assesses classification of its common stock warrants at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the criteria for equity or liability classification in the balance sheet. The warrants classified as liability are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the consolidated statements of operations at each period end while such instruments remain outstanding.

Loss per share (Tables)

Loss per share (Tables)	9 Months Ended
	Aug. 31, 2021
Loss per share
Schedule of potentially dilutive securities not considered in the computation of diluted net loss per share	​ ​ ​ ​ ​ ​ Potentially dilutive securities August 31, 2021 November 30, 2020 Series A convertible preferred stock ​ 2,280,000 ​ 2,280,000 Series B convertible preferred stock ​ 4,000,000 ​ 5,031,000 Common stock purchase warrants ​ 11,752,000 ​ 10,023,000 Stock Options ​ 3,850,000 ​ 3,850,000 Convertible Notes 2,272,000 56,000 Potentially dilutive securities 24,154,000 21,240,000

Outstanding Debt (Tables)

Outstanding Debt (Tables)	9 Months Ended
	Aug. 31, 2021
Outstanding Debt
Schedule of convertible notes payable	The table below summarizes outstanding convertible notes as of August 31, 2021 and November 30, 2020 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ August 31, 2021 November 30, 2020 Convertible Notes Payable: ​ ​ ​ ​ ​ ​ Principal value of 2020 Debenture ​ $ 300,000 ​ $ — Fair value of bifurcated contingent put option ​ 39,000 ​ — Debt discount ​ (35,000) ​ — Carrying value of 2020 Debenture ​ ​ 304,000 ​ ​ — Principal value of 2021 Debenture ​ 1,306,000 ​ — Fair value of bifurcated contingent put option ​ ​ 391,000 ​ ​ — Debt discount ​ ​ (811,000) ​ ​ — Carrying value of 2021 Debenture ​ ​ 886,000 ​ ​ — Principal value of 2019 August Debenture ​ ​ — ​ ​ 100,000 Debt discount ​ ​ — ​ ​ (8,000) Carrying value of 2019 August Debenture ​ ​ — ​ ​ 92,000 Total carrying value of convertible notes payable ​ $ 1,190,000 ​ $ 92,000
Schedule of fair value of warrants using black-scholes option pricing model using the following inputs	​ ​ ​ ​ ​ ​ ​ ​ For the nine months ​ ​ ​ ended ​ ​ August 31, 2021 Strike price ​ $ 1.25 ​ Terms (years) ​ 5.0 ​ Volatility ​ 114 % Risk-free rate ​ 0.8 % Dividend yield ​ 0 %
Summary of table presenting changes in Level 3 liabilities measured at fair value	​ ​ ​ ​ ​ Balance – December 1, 2020 $ — Additional derivative liability ​ 326,000 Debt extinguishment ​ (25,000) Change in fair value ​ 129,000 Balance – August 31, 2021 ​ $ 430,000
Schedule of discounted maximum redemption premium	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ July 26, 2021 February 12, 2021 December 23, 2020 ​ Strike price ​ $ 1.00 ​ $ 1.15 ​ $ 2.70 ​ Terms (years) ​ ​ 0.8 ​ ​ 1.0 ​ ​ 0.5 ​ Volatility ​ ​ 62 % ​ 92 % ​ 92 % Risk-free rate ​ ​ 0.1 % ​ 0.1 % ​ 0.1 % Dividend yield ​ ​ 0 % ​ 0 % ​ 0 % ​ The fair value of the contingent put option in all outstanding debentures with the feature are revalued as of August 31, 2021 based on the following weighted average key inputs: ​ ​ ​ ​ ​ ​ ​ ​ August 31, 2021 ​ ​ Strike price ​ $ 1.36 ​ ​ Terms (years) ​ ​ 0.5 ​ ​ Volatility ​ $ 0.66 ​ ​ Risk-free rate ​ ​ 0.1 % ​ Dividend yield ​ ​ 0 % ​
Schedule of interest expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the nine months ended ​ August 31, 2021 August 31, 2020 August 31, 2021 August 31, 2020 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 21,000 ​ $ 6,000 ​ $ 46,000 ​ $ 156,000 Accretion of debt discount ​ ​ 78,000 ​ ​ 3,000 ​ ​ 188,000 ​ ​ 136,000 Total interest expense ​ $ 99,000 ​ $ 9,000 ​ $ 234,000 ​ $ 292,000
2021 Debentures
Outstanding Debt
Schedule of fair value of warrants using black-scholes option pricing model using the following inputs	​ ​ ​ ​ ​ ​ Strike price $ 1.25 ​ Terms (years) ​ 5.0 ​ Volatility ​ 112 % Risk-free rate ​ 0.7 % Dividend yield ​ 0 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Aug. 31, 2021
Related Party Transactions
Schedule of general and administrative expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the nine months ended ​ August 31, 2021 August 31, 2020 August 31, 2021 August 31, 2020 Consulting and legal expenses ​ $ 105,000 ​ $ 105,000 ​ $ 315,000 ​ $ 210,000

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Aug. 31, 2021
Stockholders' Deficit
Schedule original issue price and the liquidation value per share for each class of preferred stock	The original issue price and the liquidation value per share, as of August 31, 2021, of each class of preferred stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price Liquidation Value ​ ​ Per Share ​ Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.20

Warrants and Options (Tables)

Warrants and Options (Tables)	9 Months Ended
	Aug. 31, 2021
Schedule of fair value outstanding warrants and options issued to non-employees for services	​ ​ ​ ​ ​ ​ ​ ​ For the nine months ​ ​ ​ ended ​ ​ August 31, 2021 Strike price ​ $ 1.25 ​ Terms (years) ​ 5.0 ​ Volatility ​ 114 % Risk-free rate ​ 0.8 % Dividend yield ​ 0 %
Common stock purchase warrants
Summary of warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Contractual ​ ​ ​ ​ ​ Warrants ​ Exercise Price ​ Life (years) ​ Intrinsic Value Outstanding at December 1, 2020 10,023,000 ​ $ 2.09 3.2 ​ $ 870,000 Issued 1,879,000 ​ ​ 1.25 4.8 ​ ​ — Forfeited/expired (150,000) ​ ​ — — ​ ​ — Outstanding at August 31, 2021 11,752,000 ​ $ 1.97 2.8 ​ $ 415,000 Exercisable at August 31, 2021 11,752,000 ​ $ 1.97 2.8 ​ $ 415,000
Stock Options
Schedule of Options issued for services	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at December 1, 2020 3,850,000 ​ $ 1.23 4.0 ​ $ 119,000 Issued — ​ ​ — — ​ ​ — Outstanding at August 31, 2021 3,850,000 ​ $ 1.23 4.0 ​ $ — Exercisable at August 31, 2021 3,425,000 ​ $ 1.26 2.8 ​ $ —

Loss per share (Details)

Loss per share (Details) - shares	9 Months Ended	12 Months Ended
	Aug. 31, 2021	Nov. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	24,154,000	21,240,000
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	2,280,000	2,280,000
Series B convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	4,000,000	5,031,000
Common stock purchase warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	11,752,000	10,023,000
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	3,850,000	3,850,000
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	2,272,000	56,000

Outstanding Debt (Details)

Outstanding Debt (Details) - USD ($)	Aug. 31, 2021	Nov. 30, 2020
Convertible Notes Payable:
Carrying value	$ 1,190,292	$ 92,185
Total carrying value of convertible notes payable	1,190,000	92,000
2021 Debentures
Convertible Notes Payable:
Principal value	1,306,000
Fair value of bifurcated contingent put option	391,000
Debt discount	(811,000)
Carrying value	886,000
2020 Debentures
Convertible Notes Payable:
Principal value	300,000
Fair value of bifurcated contingent put option	39,000
Debt discount	(35,000)
Carrying value	$ 304,000
2019 August Debenture
Convertible Notes Payable:
Principal value		100,000
Debt discount		(8,000)
Carrying value		$ 92,000

Outstanding Debt - Fair value o

Outstanding Debt - Fair value of measurement warrants inputs (Details)	Jul. 26, 2021Y$ / shares
Strike price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input | $ / shares	1.25
Terms (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y	5
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	112
Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.7
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0

Outstanding Debt - Fair value m

Outstanding Debt - Fair value measurement inputs (Details)	Aug. 31, 2021$ / shares	Jul. 26, 2021$ / shares	Feb. 12, 2021$ / shares	Dec. 23, 2020$ / shares
Strike price
Convertible Notes
Input	1.36	1	1.15	2.70
Terms (years)
Convertible Notes
Input	0.5	0.8	1	0.5
Volatility
Convertible Notes
Input	0.66	62	92	92
Risk-free rate
Convertible Notes
Input	0.1	0.1	0.1	0.1
Dividend yield
Convertible Notes
Input	0	0	0	0

Outstanding Debt - Changes in L

Outstanding Debt - Changes in Level 3 liabilities measured at fair value (Details)	9 Months Ended
	Aug. 31, 2021USD ($)
Outstanding Debt
Additional derivative liability	$ 326,000
Debt extinguishment	(25,000)
Change in fair value	129,000
Balance - August 31, 2021	$ 430,000

Outstanding Debt - Interest exp

Outstanding Debt - Interest expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Outstanding Debt
Interest expense based on the coupon interest rate of the outstanding debt	$ 21,000	$ 6,000	$ 46,000	$ 156,000
Accretion of debt discount	78,000	3,000	188,000	136,000
Total interest expense	$ 99,000	$ 9,000	$ 234,000	$ 292,000

Outstanding Debt - Notes Payabl

Outstanding Debt - Notes Payable - Related Parties (Details)	3 Months Ended	9 Months Ended
	Aug. 31, 2021USD ($)	Aug. 31, 2021USD ($)	Aug. 31, 2020USD ($)	Apr. 16, 2021USD ($)item
Debt Instruments [Line Items]
Repayment of notes payable - related parties	$ 30,000	$ 30,000	$ 0
Management personnel
Debt Instruments [Line Items]
Repayment of notes payable - related parties	$ 30,000
Management personnel | Unsecured promissory notes agreement
Debt Instruments [Line Items]
Number of unsecured promissory notes agreements entered | item				2
Maximum borrowing capacity of related party promissory note				$ 30,000
Interest rate (as percent)				5.00%

Outstanding Debt - Additional I

Outstanding Debt - Additional Information (Details)	Jul. 26, 2021USD ($)itemD$ / sharesshares	Feb. 12, 2021USD ($)itemD$ / shares	Dec. 23, 2020USD ($)Ditem$ / shares	Aug. 31, 2021USD ($)	Aug. 31, 2020USD ($)	Aug. 31, 2021USD ($)	Aug. 31, 2020USD ($)	Jul. 22, 2021$ / shares	May 20, 2021$ / shares
Debt Instruments [Line Items]
(Gain) loss on extinguishment of debt				$ 15,212	$ 0	$ (40,910)	$ (31,399)
Percent of prepayment from 61 to 180 days after issuance	130.00%
Exercise price | $ / shares									$ 1.25
Debentures
Debt Instruments [Line Items]
Issuance costs				170,000		170,000
Bifurcated embedded derivative						264,000
Debt discount						978,000
Beneficial conversion feature						291,000
Fair value of warrants				$ 253,000		253,000
2020 Debentures
Debt Instruments [Line Items]
Issue Of Debentures, Amount			$ 500,000
Proceeds from Issuance of Debt			$ 1,000,000
(Gain) loss on extinguishment of debt						$ 15,000
Debt Instrument, Interest Rate, Stated Percentage			5.50%
Commitment fee (as percent)			2.00%
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced			93.00%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced | item			4
Number of consecutive trading days on basis of which conversion price is reduced | D			10
Floor price of the debenture | $ / shares								$ 0.50
2020 Debentures | Maximum
Debt Instruments [Line Items]
Conversion price | $ / shares			$ 2.70
2020 Debentures | Minimum
Debt Instruments [Line Items]
Conversion price | $ / shares			$ 1
2021 Debentures
Debt Instruments [Line Items]
Issue Of Debentures, Amount	$ 806,250	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%	5.50%
Commitment fee (as percent)		2.00%
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced	85.00%	93.00%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced | item	4	4
Number of consecutive trading days on basis of which conversion price is reduced | D	20	10
Number of warrants issued | shares	645,000
Total purchase price	$ 750,000
Default interest rate	15.00%
Percent of prepayment within first 60 days of issuance	120.00%
Exercise price | $ / shares	$ 1.25
Exercisable years	5 years
Fair value of warrants	$ 253,000
2021 Debentures | Maximum
Debt Instruments [Line Items]
Conversion price | $ / shares	$ 1	$ 1.15
2021 Debentures | Minimum
Debt Instruments [Line Items]
Conversion price | $ / shares		$ 1

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	May 05, 2021	Dec. 31, 2016
Aedesius
Loss Contingencies [Line Items]
Number Of Maximum Units To Be Sold	16,000,000
Aggregate Price From Sale Of Units	$ 20,000,000
Lease agreement
Loss Contingencies [Line Items]
Lease cost per annum		$ 30,000
Renewal term (in years)		3 years

Related Party Transactions (Det

Related Party Transactions (Details)	Feb. 01, 2021USD ($)shares	Aug. 31, 2021USD ($)	Aug. 31, 2020USD ($)	Aug. 31, 2021USD ($)	Aug. 31, 2020USD ($)	Apr. 16, 2021USD ($)item
Consulting and legal expenses		$ 105,000	$ 105,000	$ 315,000	$ 210,000
Fair Value	$ 35,000
Repayment of management personnel, including all outstanding interest		30,000		$ 30,000	$ 0
Management personnel
Repayment of management personnel, including all outstanding interest		$ 30,000
Management personnel | Unsecured promissory notes agreement
Number of unsecured promissory notes agreements entered | item						2
Maximum borrowing capacity of related party promissory note						$ 30,000
Interest rate (as percent)						5.00%
Mr. Rosenstadt
Shares issued | shares	35,000

Stockholders' Deficit - Preferr

Stockholders' Deficit - Preferred Shares (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Aug. 31, 2021	May 20, 2021
Original Issue Price Per Share		$ 0.75
Series A convertible preferred stock
Original Issue Price Per Share	$ 10
Liquidation Value Per Share	10.20
Series B convertible preferred stock
Original Issue Price Per Share	10
Liquidation Value Per Share	$ 10.20
Preferred stock
Accumulated dividend on preferred stock	$ 0.1
Common Stock
Issuance common stock for dividend payment on series A and series B preferred stock	385,846

Stockholders' Deficit - Common

Stockholders' Deficit - Common Shares (Details) - USD ($)	May 20, 2021	Feb. 26, 2021	Feb. 08, 2021	Feb. 28, 2021	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Issuance of common stock for cash							$ 100,000
Share based compensation for services, Amount					$ 290,773	$ 271,430	2,244,356	$ 4,982,446
Issuance of common stock and warrants for cash (in shares)	1,213,333
Proceeds from sale of securities	$ 900,000						$ 910,000
Number of common stock shares in unit	1
Number of warrants issued per unit	1
Number of shares issuable per warrants	1
Exercise price	$ 1.25
Fair Value of Warrants Per Share	$ 0.80
Common Stock
Issuance of common stock to convert Series B preferred stock (in shares)							1,245,089
Issuance of common stock for cash							$ 100
Issuance of common stock for cash (in shares)							100,000
Share based compensation for services, Amount					$ 86	$ 124	$ 710	$ 233
Share based compensation for services, Shares					85,628	123,547	709,436
Issuance of common stock and warrants for cash (in shares)					130,833		1,213,333
Proceeds from sale of securities					$ 131		$ 1,213
Outstanding debt and interest							$ 400,000
Shares issued for conversion					301,372		469,152
Series B convertible preferred stock
Issuance of common stock to convert Series B preferred stock (in shares)				103,000
Series B convertible preferred stock | Common Stock
Share based compensation for services, Shares								233,106
Shares issued for conversion								2,811,198
Common Stock
Issuance of common stock to convert Series B preferred stock (in shares)				1,245,089
Issuance of common stock for cash		$ 100,000
Issuance of common stock for cash (in shares)		100,000
Shares of common stock issued as dividend payment			130,833
General and Administrative Expense
Share based compensation for services, Amount							$ 700,000
Share based compensation for services, Shares							709,436

Warrants and Options - Summary

Warrants and Options - Summary of warrants (Details) - Common stock purchase warrants - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2021	Nov. 30, 2020
Warrants
Beginning balance	10,023,000
Issued	1,879,000
Forfeited/expired	(150,000)
Ending balance	11,752,000	10,023,000
Exercisable at August 31, 2021	11,752,000
Weighted Average Exercise Price
Beginning balance	$ 2.09
Issued	1.25
Ending balance	$ 1.97	$ 2.09
Exercisable at August 31, 2021	1.97
Weighted Average Remaining Contractual Life (years)
Beginning balance		3 years 2 months 12 days
Issued	4 years 9 months 18 days
Forfeited/expired	0 years
Ending balance	2 years 9 months 18 days
Exercisable at August 31, 2021	2 years 9 months 18 days
Intrinsic Value
Beginning balance		$ 870,000
Ending balance	$ 415,000
Exercisable at August 31, 2021	$ 415,000

Warrants and Options - Fair val

Warrants and Options - Fair value of warrants (Details) - Stock Options	May 20, 2021$ / shares
Strike price	$ 1.25
Term (years)	5 years
Volatility	114.00%
Risk-free rate	0.80%
Dividend yield	0.00%

Warrants and Options - Summar_2

Warrants and Options - Summary of outstanding options (Details) - Stock Options	9 Months Ended	12 Months Ended
	Aug. 31, 2021$ / sharesshares	Nov. 30, 2020$ / sharesshares
Options
Beginning balance | shares	3,850,000
Ending balance | shares	3,850,000	3,850,000
Exercisable at August 31, 2021 | shares	3,425,000
Weighted Average Exercise Price
Beginning balance	$ 1.23
Ending balance	$ 1.23	$ 1.23
Exercisable at August 31, 2021	1.26
Weighted Average Remaining Contractual Life (years)
Beginning balance		4 years
Issued	0 years
Ending balance	4 years
Exercisable at August 31, 2021	2 years 9 months 18 days
Intrinsic Value
Beginning balance		$ 119,000

Warrants and Options - Addition

Warrants and Options - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020	May 20, 2021
Share based compensation related to warrants modification, Amount				$ 255,008
Exercise price per share					$ 0.75
Share based compensation for services			$ 2,244,356	4,982,446
Exercise price of warrant					$ 1.25
General and administrative expenses	$ 1,371,676	$ 1,491,613	5,028,668	8,659,819
Research and development expenses	202,168	$ 613,707	667,538	896,908
Unrecognized stock-based compensation	$ 56,000,000,000		56,000,000,000
Options And Warrants [Member]
General and administrative expenses			$ 2,200,000
Research and development expenses				$ 5,000,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)	Sep. 29, 2021USD ($)D$ / shares	Sep. 02, 2021shares	Sep. 30, 2021USD ($)shares	Aug. 31, 2021shares	Nov. 30, 2020shares
Subsequent Event [Line Items]
Issued shares of common stock | shares				27,974,345	23,816,489
Subsequent Event
Subsequent Event [Line Items]
Aggregate principal amount including original issue discount and Lender's legal fees	$ 2,200,000
Original issue discount	185,000
Lender's legal fees	$ 15,000
Percent of prepayment from 121 to 180 days after issuance	6.00%
Percent of prepayment within first 60 days of issuance	105.00%
Percent of prepayment from 61-120 days after issuance	112.00%
Percent of prepayment from 121 to 180 days after issuance	124.00%
Conversion price | $ / shares	$ 1
Conversion price after six months | $ / shares	$ 0.50
Debt Instrument, Convertible, Threshold Consecutive Trading Days | D	10
Debt Conversion, Reduction in Conversion Price, Percentage of Average of Lowest Daily Volume Weighted Average Prices	85.00%
Debt Conversion, Reduction in Conversion Price, Number of Lowest Daily Volume Weighted Average Prices During the Consecutive Trading Days | D	4
Number of prior trading days in conversion price | D	20
Subsequent Event | Common Stock
Subsequent Event [Line Items]
Issued shares of common stock | shares			476,479
Outstanding debt and interest			$ 300,000
Subsequent Event | Series A [Member]
Subsequent Event [Line Items]
Issued shares of common stock as dividend | shares		147,764
Subsequent Event | Series B [Member]
Subsequent Event [Line Items]
Issued shares of common stock as dividend | shares		147,764
Subsequent Event | Securities purchase agreement
Subsequent Event [Line Items]
Maturity date	12 months
Gross aggregate principal amount	$ 2,000,000
Subsequent Event | Maximum
Subsequent Event [Line Items]
Conversion price after six months | $ / shares	$ 0.50